INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 285 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,433,247 | +669.5% | 203,455 | +892.5% | 0.02% | +466.7% |
| Q2 2023 | $835,990 | -86.2% | 20,500 | -87.4% | 0.00% | -96.7% |
| Q1 2023 | $6,041,616 | +20.1% | 162,104 | +12.4% | 0.09% | -2.2% |
| Q4 2022 | $5,031,975 | +206.3% | 144,224 | +391.2% | 0.09% | +187.5% |
| Q3 2022 | $1,643,000 | -55.2% | 29,361 | -41.9% | 0.03% | -67.3% |
| Q1 2022 | $3,671,000 | +321.0% | 50,521 | +585.1% | 0.10% | +263.0% |
| Q4 2021 | $872,000 | +505.6% | 7,374 | -37.4% | 0.03% | -15.6% |
| Q1 2020 | $144,000 | -69.6% | 11,785 | -63.5% | 0.03% | +6.7% |
| Q4 2019 | $474,000 | +39.8% | 32,297 | +27.6% | 0.03% | +50.0% |
| Q3 2019 | $339,000 | -13.7% | 25,321 | +5.5% | 0.02% | -53.5% |
| Q2 2019 | $393,000 | -35.1% | 24,000 | -32.4% | 0.04% | -56.6% |
| Q1 2019 | $606,000 | – | 35,500 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 752,024 | $100,884,000 | 18.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 420,859 | $56,458,000 | 4.40% |
| Discovery Value Fund | 922,411 | $123,741,000 | 3.63% |
| MPM BioImpact LLC | 162,620 | $21,815,000 | 3.38% |
| Ally Bridge Group (NY) LLC | 65,000 | $8,720,000 | 2.56% |
| ARK Investment Management | 6,743,556 | $904,648,000 | 2.17% |
| Integral Health Asset Management, LLC | 50,000 | $6,708,000 | 1.93% |
| Yorktown Management & Research Co Inc | 18,300 | $2,455,000 | 1.85% |
| Interchange Capital Partners, LLC | 8,191 | $1,098,000 | 1.84% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $14,950,000 | 1.76% |